- Home
- GNLX vs UNCY Comparison
GNLX vs UNCY Comparison
Compare GNLX & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLX | UNCY |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.8M | 141.8M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GNLX | UNCY |
|---|---|---|
| Price | $2.70 | $6.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $19.75 | ★ $44.50 |
| AVG Volume (30 Days) | 181.8K | ★ 484.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.10 | ★ 56.25 |
| EPS | ★ N/A | N/A |
| Revenue | $8,000.00 | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $0.45 |
| 52 Week High | $8.54 | $7.57 |
Technical Indicators
Market Signals| Indicator | GNLX | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 45.03 | 54.42 |
| Support Level | $2.31 | $5.90 |
| Resistance Level | $2.80 | $6.82 |
| Average True Range (ATR) | 0.16 | 0.35 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 51.13 | 75.70 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.